Skip to main content
SpringerLink
Log in

Perioperative Safety of Aprotinin in Coronary Artery Bypass Graft Surgery

Is there Life After BART?

  • Commentary
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mangano DT, Tudor JC, Dietzel C. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation: the risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353–65

    Article  PubMed  CAS  Google Scholar 

  2. Augoustides J. Con: aprotinin should not be used in cardiac surgery with cardiopulmonary bypass. J Cardiothor Vasc Anesth 2007; 21: 302–4

    Article  Google Scholar 

  3. Brown JR, Birkmeyer NJO, O’Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007; 115: 2801–13

    Article  PubMed  CAS  Google Scholar 

  4. Henry DA, Carless PA, Moxey AJ, et al. Antifibrinolytic use for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007; 4: CD001886

  5. Fergusson D, Glass KC, Hutton B, et al. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clin Trials 2005; 2: 218–30

    Article  PubMed  Google Scholar 

  6. Augoustides JG, Fleisher LA. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clin Trials 2005; 2: 231–2

    Google Scholar 

  7. Bayer HealthCare Pharmaceuticals. Important trasylol safety information. November 5, 2007 [online]. Available from URL: http://www.trasylol.com [Accessed 2008May 27]

  8. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319–31

    Article  PubMed  CAS  Google Scholar 

  9. Ray WA, Stein CM. The aprotinin story: is BART the final chapter? N Engl J Med 2008; 358: 2398–400

    Article  PubMed  CAS  Google Scholar 

  10. Kluth M, Lueth JU, Zittermann A, et al. Low-dose aprotinin use is not associated with adverse effects on safety variables in coronary artery bypass graft surgery. Drug Saf 2008; 31(7): 617–26

    Article  PubMed  CAS  Google Scholar 

  11. Strouch ZY, Chaney MA, Augoustides JG, et al. Case 1–2008: one institution’s decreasing use of aprotinin during cardiac surgery in 2006. J Cardiothorac Vasc Anesth 2008; 22: 139–46

    Article  PubMed  Google Scholar 

  12. Kincaid EH, Ashburn DA, Hoyle JR, et al. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery? Ann Thorac Surg 2005; 80: 1388–93

    Article  PubMed  Google Scholar 

  13. Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008; 358: 784–93

    Article  PubMed  CAS  Google Scholar 

  14. Schneeweiss S, Seeger JD, Landon J, et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008; 358: 771–83

    Article  PubMed  CAS  Google Scholar 

  15. Pagano G, Howell NJ, Freemantle N, et al. Bleeding in cardiac surgery: the use of aprotinin does not affect survival. J Thorac Cardiovasc Surg 2008; 135: 495–502

    Article  PubMed  Google Scholar 

  16. US Food and Drug Administration. FDA clinical advisory on aprotinin [online]. Available from URL: http://www.fda.gov/cder/infopage/aprotinin/defaulthtm [Accessed 2008 May 27]

  17. Dietrich W, Busley R, Kriner M. High-dose aprotinin in cardiac surgery: is high-dose enough? An analysis of 8281 cardiac surgical patients treated with aprotinin. Anesth Analg 2006; 103: 1074–81

    Article  PubMed  CAS  Google Scholar 

  18. Ferguson TB. Aprotinin: are there lessons learned. JAMA 297: 527–529

  19. Ray WA. Learning from aprotinin-mandatory trials of compar-ative efficacy and safety needed. N Engl J Med 2008; 358: 840–2

    Article  PubMed  CAS  Google Scholar 

  20. Sundt TM. The demise of aprotinin: our share of the blame. J Thorac Cardiovasc Surg 2008; 135: 729–31

    Article  PubMed  Google Scholar 

  21. Apostolakis E, Panagopoulos H, Koletsis EN, et al. Influence of ultra-low dose aprotinin on thoracic surgical procedures: a prospective randomized trial. J Cardiothorac Surg 2008 Mar 24; 3: 14

    Article  PubMed  Google Scholar 

  22. Shuhaiber JH, Goldsmith K, Large SR, et al. Does perioperative use of aprotinin reduce the rejection rate in heart transplant recipients? Eur J Cardiothorac Surg 2008; 33(5): 849–55

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Financial support was provided by the Department of Anesthesiology and Critical Care, Hospital of the University of Pennsylvania. The author has no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Cardiothoracic and Vascular Section, Anesthesiology and Critical Care, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, Pennsylvania, 19104-4283, USA

    John G. Augoustides

Authors
  1. John G. Augoustides
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John G. Augoustides.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Augoustides, J.G. Perioperative Safety of Aprotinin in Coronary Artery Bypass Graft Surgery. Drug-Safety 31, 557–560 (2008). https://doi.org/10.2165/00002018-200831070-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200831070-00001

Keywords

Search

Navigation